Nutrition, genetic variation and male fertility.

Infertility affects nearly 50 million couples worldwide, with 40-50% of cases having a male factor component. It is well established that nutritional status impacts reproductive development, health and function, although the exact mechanisms have not been fully elucidated. Genetic variation that affects nutrient metabolism may impact fertility through nutrigenetic mechanisms. This review summarizes current knowledge on the role of several dietary components (vitamins A, B12, C, D, E, folate, betaine, choline, calcium, iron, caffeine, fiber, sugar, dietary fat, and gluten) in male reproductive health. Evidence of gene-nutrient interactions and their potential effect on fertility is also examined. Understanding the relationship between genetic variation, nutrition and male fertility is key to developing personalized, DNA-based dietary recommendations to enhance the fertility of men who have difficulty conceiving.

A Randomized, Double-Blind, Controlled Trial Shows that Onabotulinum Toxin A Nerve Blocks do Not Provide Improved Pain Control in Men with Chronic Scrotal Pain.

PURPOSE: The use of onabotulinum toxin A to chemically denervate the testis has been studied as a minimally invasive therapy to treat chronic scrotal pain. To our knowledge no randomized, controlled trials of onabotulinum toxin A for chronic scrotal pain management have been reported to date. MATERIALS AND METHODS: In this double-blind, randomized, controlled trial men with chronic scrotal pain who achieved at least temporary pain relief following a cord block with local anesthesia were randomly assigned to a block using local anesthesia alone vs local anesthesia plus 200 IU onabotulinum toxin A. Standardized assessments of pain levels using a visual analogue score, disease impact, quality of life and mood were performed 1, 2, 3, 4, 12 and 18 weeks after injection. The study primary outcome was the change in the visual analogue score at 1 month. After study completion the men in the control group were given the option to receive onabotulinum toxin A as part of an open label trial. RESULTS: Of 64 men with a mean ± SD age of 45.9 ± 11 years and a mean 5.7 ± 5.7-year history of pain 32 received local anesthesia plus onabotulinum toxin A and 32 received local anesthesia alone. There was no statistically significant difference in any measured outcome when comparing those who received onabotulinum toxin A to controls. Nine of the 13 men (69.2%) in the open label trial achieved an improvement in the visual analogue score (mean group score 6.1 ± 1.66 to 4.5 ± 2.36, Student t-test p=0.022) with a reduction in persistent pain at 3 months in 6 of the 9 (66.7%). CONCLUSIONS: This randomized, double-blind, controlled trial showed no superiority of onabotulinum toxin A plus local anesthesia over local anesthesia alone for pain control in men with chronic scrotal pain. Interestingly, significant pain improvement was noted in our open label onabotulinum toxin A trial, suggesting a potential placebo effect.

Penile frenuloplasty: a simple and effective treatment for frenular pain or scarring.

UNLABELLED: Study Type - Therapy (case series) Level of Evidence 4. What's known on the subject? and What does the study add? Frenuloplasty, using common plastic surgical techniques for scar lengthening, is a commonly performed operation amongst urologists for isolated frenular pathology. However, there is very little data in the urological literature regarding either technique or assessment. The only other published study was a questionnaire follow-up with a 23% response rate and the technique used was not clarified. Other studies describe expensive, rarely used procedures and are hampered by small patient numbers or short-term follow-up only. Our study validates the common practice of using plastic surgical techniques for scar lengthening. We have 100% clinical short-term follow-up (3 months) and 91% long-term follow-up (up to 10 years) showing high patient satisfaction scores and low complication and re-operation rates. This provides an evidence base from which to counsel patients who are keen for foreskin sparing surgery for frenular pathology. The extra addition of our grading system allows patients to be risk-stratified as to the risk of re-operation depending on their status at presentation and underlying pathology. OBJECTIVE: To assess the long-term patient satisfaction and outcomes for penile frenuloplasty when offered as an alternative to circumcision for frenular pain and/or scarring. PATIENTS AND METHODS: Data was prospectively collected over 10 years, for a total of 106 men. The nature of the frenular problem was graded. Techniques of V-Y plasty, Z-plasty or a combination of the two were used. All patients were reviewed at 3 months and contacted via questionnaire ≥ 1 year after surgery. The questionnaire assessed satisfaction, cosmetic appearance, pain on intercourse, need for subsequent surgery and if they would recommend the procedure to a friend. RESULTS: Follow-up was 100% (106/106) at 3 months and 91% (96/106) ≥ 1 year. Patient satisfaction and cosmesis scores both averaged 8.9/10. Need for subsequent circumcision was 8% (9/96). There were minor complications (bruising/infection/partial dehiscence) in 8% (9/96) of patients. 97% (84/87) of patients would recommend the procedure to a friend. CONCLUSIONS: Penile frenuloplasty is a safe alternative to circumcision. There are high patient satisfaction rates after surgery. Low numbers of patients require a completion circumcision after penile frenuloplasty.